Stomach cancer (credit: canva)
Stomach cancer is a type of cancer that develops in the lining of the stomach. Also, known as Gastric cancer, it affects the elderly more than the adult. According to the American Cancer Society, about 6 of every 10 people diagnosed with stomach cancer each year are 65 or older. Also, the lifetime risk of developing stomach cancer is higher in men (about 1 in 101) than in women (about 1 in 155).
A health expert, speaking to a leading media house, emphasized five common symptoms of stomach cancer that should not be ignored:
1. Unexplained weight loss: Losing weight without trying or experiencing an unexplained drop in appetite, which may signal cancer progression.
2. Pain in the upper part of the abdomen: Persistent or occasional pain in the stomach area, often after eating, can become more severe as the condition progresses.
3. Frequent vomiting after meals: Nausea, sometimes accompanied by vomiting, may occur especially after meals and is linked to cancer blocking or irritating the stomach.
4. Vomiting blood, which may appear coffee-colored: This can indicate bleeding in the stomach, often caused by ulcers or tumors, and requires immediate medical attention.
5. Black, tarry stools: This occurs when blood from the stomach is digested and passed through the intestines, signaling potential internal bleeding
There are also other concerning signs that should not be overlooked such as jaundice, unexplained weight loss, early onset of diabetes, dark stools, and loss of appetite. Health experts strongly advise seeking immediate medical attention if you notice any of these symptoms. If you or a loved one experience these signs, it's crucial to visit a physician for a thorough evaluation to rule out serious underlying health conditions.
Oncologist Dr Pankaj Kumar Pande, Director–Surgical Oncology, Max Super Specialty Hospital, Shalimar Bagh, Delhi explained that this form of cancer spreads through three main pathways: Direct spread, lymphatic spread, and bloodstream.
1. Direct Spread: In its early stages, stomach cancer can invade nearby tissues and grow into the deeper layers of the stomach or spread to surrounding organs such as the oesophagus, liver, pancreas, or intestines.
2. Lymphatic Spread: Cancer cells can travel through the lymphatic system. The most common areas affected are the regional lymph nodes near the stomach, particularly those around the liver and diaphragm.
3. Bloodstream: "Cancer cells can enter the bloodstream and travel to distant parts of the body," which is a common route for stomach cancer to metastasize to distant organs.
He further explained that cancerous cells spread from the original tumour to other parts of the body through a process called Metastasis. The most common sites for the spread are the liver, lymph nodes, peritoneum, lungs, bones, and ovaries.
Credit: AI Image
A new trial by Novo Nordisk found that Wegovy (semaglutide) reduced body mass index (BMI) by at least 10% in nearly 80% of children with obesity aged 6 to under 12 years.
The phase 3 STEP Young trial found that 78.7% of children receiving semaglutide achieved this reduction after 68 weeks, compared with none in the placebo group.
However, the findings raise questions about the safety of GLP-1 medications in younger children. The World Health Organization (WHO) does not recommend weight-loss medicines for treating obesity in children under 10, citing limited evidence on their long-term safety and effectiveness.
Also read: Wegovy & Zepbound Are Not Approved By US FDA For Children Under 12: So Why Are Prescriptions Rising?
The phase 3 trial evaluated once-weekly semaglutide injections in children aged 6 to under 12 with obesity. Participants also followed a reduced-calorie diet and increased their physical activity.
The findings were presented at ObesityWeek 2026 and published in The New England Journal of Medicine.
After 68 weeks:
Childhood obesity increases the risk of type 2 diabetes, high blood pressure, abnormal cholesterol levels and obstructive sleep apnea. Severe obesity can also affect a child's physical health, emotional well-being and daily life, with complications that may persist into adulthood.
The trial also found improvements in multiple cardiometabolic measures among children receiving semaglutide.
"Encouragingly, treating obesity with semaglutide was accompanied by improvements in multiple cardiometabolic measures, suggesting that effective treatments for severe childhood obesity may shift a child's trajectory back towards one of improving weight-related health," said Ania M. Jastreboff, Professor of Medicine and Pediatrics at Yale School of Medicine and Director of the Yale Obesity Research Center.
What Are The Side Effects?
Read More: Are GLP-1 Drugs Safe for Children? Study Finds Nutritional Deficiency in Nearly 17% Within a Year
Adverse events were reported in 96% of children receiving semaglutide and 93% receiving placebo. Gastrointestinal problems were the most common and occurred more frequently among children taking the drug.
Common gastrointestinal side effects associated with semaglutide include nausea, vomiting, diarrhoea, constipation and abdominal pain.
Other potential risks associated with GLP-1 treatment include gallbladder problems, pancreatitis and dehydration.
The WHO does not recommend weight-loss medicines, bariatric surgery or weight-management devices for children aged 0 to 9, as there is insufficient evidence on GLP-1 drugs in younger populations.
Instead, it recommends healthy eating, physical activity and behavioural support for children and their caregivers.
For adolescents aged 10 to 19, approved obesity medicines may be considered alongside structured lifestyle interventions.
Read More: Childhood Obesity In India To Surge To 56 Million By 2040, Says Global Report
Despite these recommendations, GLP-1 prescriptions among younger children in the US are rising.
A NYU Langone Health study analysing health records of more than 3.5 million children found that prescriptions among those aged 8 to 11 with obesity increased more than 300-fold between 2019 and June 2026.
The GLP-1 medications approved for adolescents by the US FDA are not necessarily approved for children under 12.
However, a study from Northwestern University and Ann & Robert H. Lurie Children's Hospital of Chicago flagged nutritional deficiencies among young children taking GLP-drugs.
It showed that 16.8% of children aged 10 to 17 receiving GLP-1 medications developed a nutritional deficiency within a year. Vitamin D deficiency was the most common, affecting 12.4% of patients.
Amid limited long-term safety data, experts are concerned about prescribing appetite-suppressing drugs to children who are still growing, particularly because reduced appetite could lead to inadequate calorie and nutrient intake.
Credit: Health Ministry/X
Malaria cases and deaths in India declined by nearly 80% between 2015 and 2025, President Droupadi Murmu said on Tuesday, while warning that climate change, unplanned urbanization and growing mosquito resistance could create new challenges for malaria elimination.
Speaking at the inauguration of the Golden Jubilee celebrations of the Indian Council of Medical Research–National Institute of Malaria Research (ICMR–NIMR), the President called for sustained vigilance, stronger surveillance and greater community participation to achieve malaria elimination.
The President noted that malaria remains a serious public health challenge in several countries, including India.
Recalling the situation at the time of independence, she said the vector-borne disease was among the country's most critical public health challenges. She also shared her personal observations of how malaria affected people's lives.
"During the monsoon season, fever was often accepted as an inevitable hardship of life. Children were unable to attend school, while farmers and laborers were often left unable to work for days on end. For the people, malaria was not merely a health issue—it was deeply intertwined with their livelihoods, education, and future," she said.
India has since made significant progress through sustained public health interventions. Between 2015 and 2025, malaria cases and deaths declined by nearly 80%, while the number of high-burden districts fell from 155 to 33.
As many as 160 districts reported zero indigenous malaria cases between 2022 and 2025, reflecting progress in interrupting local transmission and implementing targeted malaria control and elimination measures.
Calling the progress "remarkable", the President credited improved healthcare services, modern diagnostic techniques, effective medicines, mosquito-control campaigns and community participation for curbing the disease.
Also read: El Niño Could Worsen Dengue, Malaria And Heat Illness: Why WHO Declared A Health Emergency
Despite the progress, malaria remains a challenge in certain regions, the President said, stressing the need for "sustained vigilance and effective efforts" to eliminate the disease.
She highlighted the importance of robust systems for malaria testing, treatment, surveillance and mosquito control.
Research aimed at developing new drugs and vaccines, along with public awareness and community participation, will also be vital for malaria elimination, she said.
The President warned that climate change, unplanned urbanization and growing mosquito resistance to insecticides could create new obstacles to malaria elimination efforts.
She also urged citizens to contribute to prevention efforts by avoiding water stagnation, eliminating mosquito breeding sites and maintaining a clean environment.
Beyond malaria, she noted that rising global temperatures and shifting monsoon patterns are further intensifying the challenge posed by dengue.
Addressing the gathering, Union Minister of Health and Family Welfare Jagat Prakash Nadda said India's progress in malaria control over the past decade was the result of a comprehensive approach involving research on mosquito behaviour and malaria parasites, community participation, effective prevention, early diagnosis and appropriate treatment.
Highlighting India's progress in malaria control, Nadda noted that the country, which accounts for approximately 16% of the global population, contributes around 0.7% of global malaria cases and 0.6% of malaria deaths.
The Union Minister also appreciated India's exit from the WHO's High Burden to High Impact initiative and expressed confidence in achieving malaria elimination by 2030.
"We will eliminate malaria by 2030 by bringing about the necessary changes in our strategies and policies," he said, calling upon ICMR–NIMR to work with renewed commitment.
The Minister also highlighted ICMR's contributions to medical innovation, including MedTech Mitra, Patent Mitra and ELISA-based molecular diagnostics for dengue, chikungunya, Japanese encephalitis and other infectious diseases.
Credit: AI-generated image
Faulty radon detectors have sparked concern after Health Canada issued a warning about how inaccurate readings on devices sold online could mislead consumers. The advisory issued recently says that faulty detectors could underestimate radon levels, giving consumers a false sense of security about their exposure to the cancer-causing gas.
It talks about electronic radon monitors and home-testing kits that have previously recalled after it was found that they gave inaccurate readings.
Among the products Health Canada has previously warned against are the InkBird WiFi Radon Detector (model RD-2), Life Basis radon detectors, Hanchen Home Radon Detector and Spolehli radon detectors. The agency has also issued warnings about other radon-monitoring devices sold online.
Inaccurate readings can be problematic in both ways. A detector may report radon levels lower than they actually are, leaving people exposed to dangerous concentrations without their knowledge. On the other hand, it may report higher levels than those present, causing unnecessary panic.
Health Canada recommends that consumers choose electronic radon monitors that have passed performance testing by the Canadian National Radon Proficiency Program (C-NRPP).
Radon is a naturally occurring radioactive gas released when uranium in soil and rocks breaks down. It is invisible, odourless and tasteless, making it impossible to detect without specialised equipment.
The gas can enter buildings through cracks in foundations, gaps around pipes, floor drains and other openings.
While radon disperses quickly in outdoor air, it can accumulate to high concentrations indoors, especially basements and poorly-ventilated areas.
Long-term exposure to highradon levels increases the risk of lung cancer. According to Health Canada, radon is the second-leading cause of lung cancer in Canada after smoking and the leading cause among people who have never smoked.
The risk depends on both the concentration of radon in the air and how long a person is exposed. People who smoke and are exposed to radon face an even greater risk of lung cancer.
Also read: Daraxonrasib: Europe Approves First RAS-Targeted Drug For Metastatic Pancreatic Cancer
Radon decays into radioactive particles that can be inhaled through breathing. These particles release radiation that can damage the DNA of lung cells. Long-time exposure can lead to genetic changes that contribute to cancer.
The International Agency for Research on Cancer (IARC) classifies radon as a Group 1 carcinogen, meaning there is sufficient evidence that it causes cancer in humans.
Health Canada recommends long-term testing to determine the average radon concentration in your home. A test lasting at least three months provides a more reliable assessment than short-term measurements because radon levels can fluctuate with weather, ventilation and seasonal changes.
Consumers should:
Health Canada's guideline for indoor radon is 200 becquerels per cubic metre (Bq/m³). If the average level is above this threshold, homeowners should take action within one year and consult a certified professional.
© $2026 Times Horizon Private Limited